Introduction: Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD) characterized by a relapsing-remitting course owing to recurrent intestinal inflammation. UC often has symptoms such as intermittent rectal bleeding, diarrhea, and abdominal pain. As the precise etiology of UC has not completely clarified, UC has become a public health challenge worldwide. According to an epidemiological survey, there were about 350,000 new cases of IBD in China from 2005 to 2014. By 2025, the number of IBD patients in China will reach 1.5 million. Traditional Chinese medicine (TCM) has been widely used to treat UC in China, however, it is still challenging to systematically determine the efficacy of in UC. Therefore, this trial aims to evaluate the clinical efficacy and safety of CHM in the treatment of mild active UC patients. Methods: A multi-center, double-blinding, double-dummy, active-controlled, randomized trial will be established. A total of 240 patients in 6 centers with mild active UC (Mayo score is 3–5 points) and TCM syndrome of damp-heat stasis blocking and spleen-qi deficiency will be randomly allocated in the ratio of 1:1 to 2 groups: the experimental group and the control group. The experimental group will receive Hudi enteric-coated capsules (HEC) and enteric-coated mesalazine tablets placebo; the control group will receive enteric-coated mesalazine tablets and HEC placebo. Each group will be treated for 8 weeks. The primary therapeutic outcome: the rate of clinical efficacy and clinical remission at 8 weeks of treatment (last survey point) according to the modified Mayo score. The secondary outcomes: individual symptom score, TCM syndrome score, endoscopic response rate, mucosal healing rate, and quality of life scale score. Outcomes will be assessed at baseline and the end of the trial. Besides, intestinal mucosa, stools and blood biopsies from the mild active UC patients before and after treatment will be collected to reveal the underlying mechanisms. Discussion: The results of this trial will provide compelling evidence of the efficacy and safety of HEC for treatment of mild active UC and preliminarily show the potential mechanism of how HEC acts. Finally, it will widen treatment options for patients with mild active UC.

No abstract

Objective Knee osteoarthritis is a prevalent degenerative joint disease and seriously affects the athletic abilities of middle-aged and elderly patients. Acupressure is a traditional non-pharmacological intervention that promotes blood circulation and muscle activity. Self-administrated acupressure and exercise can be potential management for knee osteoarthritis. Design It is a randomized and controlled trial for knee osteoarthritis self-treatment. Settings Cangzhou Hospital. Interventions 221 patients with knee osteoarthritis were recruited and randomly divided into 4 groups: control group ( n = 55), exercise group ( n = 56), acupressure group ( n = 55) and exercise & acupressure group ( n = 55). In the first eight weeks, corresponding training courses were provided to different groups of patients. The patients were asked to carry out their own corresponding interventions for 16 weeks. The patient‘s condition was evaluated in the sixteenth week. Main measures The Western Ontario and McMaster Universities global scores of knee osteoarthritis patients were assessed at the 8th and 16th week of our trial. Results Self-administered acupressure and exercise significantly decreased visual analogue scale (3.75 ± 1.89 versus 2.93 ± 1.73, p < 0.05), pain (7.6 ± 2.8 versus 4.8 ± 2.7, p < 0.05), stiffness (3.75 ± 1.89 versus 2.93 ± 1.73, p < 0.05) at the 16th week ( p < 0.05) in patients with knee osteoarthritis compared to other intervention. The combination of acupressure and exercise also improved the range of motion (114.4 ± 11.5 versus 120.4 ± 11.9, p < 0.05) and walk speed (1.48 ± 0.48 versus 1.76 ± 0.50, p < 0.05) of osteoarthritis patients ( p < 0.05). Conclusion Self-administrated exercise and acupressure alleviate the arthritic symptoms (swelling, pain, joint dysfunction and joint deformities) and improve the joint functions, supporting its potential use in the clinical management for osteoarthritis.

Giant cell tumor of bone is a well-recongnized primary bone tumor. It is considered a borderline tumor that can recur locally following curettage, rarely malignancy, and rarely metastasizes to the lungs. Giant cell tumor of bone was first described by Jaffe in 1940. But multicentric giant cell tumor of bone is rare and accounts for less than 1% of all giant cell tumor. To our knowledge, most published reports on this condition have been single cases, descriptions or studies of small series [1][2][3][4][5][6] , the largest series to date was 30 cases [7] , and none were reported in domestic literature. In this investigation, we describe the clinicopathologic findings of nine cases of multicentric giant cell tumor of bone and review the literature. , all patients who had been diagnosed with a giant cell tumor of bone were searched at the Affiliated Provincal Hospital of Shandong University. Three male and six female. The age at the time of the initial presentation was ranged from 15-45 years (average 22.3 years). Three of the patients were younger than twenty years of age, and only one patient was older than forty years. A total of twenty tumors were found in nine patients, in which five patients had two tumors, three patients three tumors and one patient four tumors . LocationMost tumors arose in long bones. The distal part of the femur and the proximal part of the tibia were the most frequent locations (8 tumors). None of these tumors extended across the knee joint. The next most frequent locations were the distal part of the radius (3 tumors), proximal part of the humerus (2 tumors), and proximal part of the fibular (2 tumors). There was a separate lesion involving the cervical vertebral, the fifth metatarsalgia, the proximal part of the femur, the distal part of the tibia, and the ilium (Fig. 1).Abstract Objective: The aim of this study was to investigate the clinical, radiographic and histiopathologic features of multicentric giant cell tumor of bone. Methods: All the clinical data of twenty tumors in nine patients of multicentric giant cell tumor that underwent surgical treatment in our department from 1990 to 2010 were retrospectively reviewed, which included three males and six females. The patients ranged from 15 to 45 years at diagnosis, with an average age of 22.3 years. Three of the patients were younger than twenty years of age. Most tumors arose in long bones, especially around the knee. Radiographically, the tumors in long bones usually manifested as expansive lytic lesions involving the metaphysis and extending into the epiphysis. Three tumors in three patients were confined to the metaphysis, and one tumor exhibited bone-forming lesions. All tumors were treated with curettage or resection. Results: The typical "giant cell" could be found in the oncologic examination in all cases. In some areas, such as the fibrohistiocytic regions, reactive bone forming and aneurysmal bone cyst-like changes could be found. Follow-up averaged 3.5 years, ranging from 6 months to 12 years. There was a recurrence of t...